Rxsight Inc (RXST)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $223.06M
Last updated: Nov 17, 2026 at 4:10 PM ET
Rxsight Inc (RXST) Statistics
Rxsight (RXST) has a market cap of $223.06M and an enterprise value of $164.82M. It kept -43.80% of revenue as net income over the last 12 months. It holds $58.24M more cash than debt, 26.11% of its market cap.
Total Valuation
Enterprise value is 26.11% below the market cap, as cash exceeds debt.
| Market Cap | $223.06M |
|---|---|
| Enterprise Value | $164.82M |
| Latest price (Nov 17, 2026) | $4.83 |
Key Dates
| Last Earnings Date | Nov 3, 2026 |
|---|---|
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 1.7x and 0.8x. Its year-end P/S ranged from 3.2x to 15.7x from 2021 to 2025.
| P/S Ratio | 1.7x |
|---|---|
| Forward P/S | 1.5x |
| P/B Ratio | 0.8x |
| P/FCF Ratio | 10.8x |
| P/OCF Ratio | 9.4x |
Enterprise Valuation
Counting debt and cash, the company is valued at 7.7x free cash flow.
| EV / Sales | 1.4x |
|---|---|
| EV / FCF | 7.7x |
Price Statistics
The stock is down 50.36% over 52 weeks and trades 3.21% below its 50-day average.
| Beta (1Y) | 1.36 |
|---|---|
| 52-Week Change | -50.36% |
| 1-Month Change | +2.99% |
| 3-Month Change | -21.59% |
| 6-Month Change | -18.82% |
| 5-Year Change | -59.35% |
| Total Return (1Y) | -50.36% |
| Total Return (3Y CAGR) | -44.01% |
| Total Return (5Y CAGR) | -17.72% |
| Return vs SPY (1Y) | -61.25% |
| Max Drawdown (1Y) | -65.55% |
| Max Drawdown (3Y) | -92.98% |
| Sharpe Ratio (1Y) | -1.09 |
| Correlation with SPY (1Y) | 0.29 |
| 50-Day Average | $4.99 |
| 200-Day Average | $6.10 |
| 52-Week Range | $4.11 to $13.22 |
| RSI (14 Days) | 46.5 |
| Average Volume (20 Days) | 943.53K |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 4.20x current liabilities, and total debt is 0.03x shareholder equity.
| Current Ratio | 4.20x |
|---|---|
| Quick Ratio | 3.67x |
| Debt / Equity | 0.03x |
| Debt / FCF | 0.45x |
| Interest Coverage | -4727.15x |
Returns and Efficiency
Return on invested capital is -23.33% over the last 12 months, against a 5-year average of -16.88%.
| Return on Equity (ROE) | -20.93% |
|---|---|
| Return on Assets (ROA) | -15.67% |
| Return on Invested Capital (ROIC) | -23.33% |
| ROE (5Y Average) | -32.73% |
| ROA (5Y Average) | -23.49% |
| ROIC (5Y Average) | -16.88% |
| Asset Turnover | 0.38x |
| Inventory Turnover | 0.38x |
| Receivables Turnover | 2.55x |
| Cash Conversion Cycle | 972 days |
Scores
RXST has an Altman Z-Score of -0.88, in the distress zone below 1.81, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -0.88 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 2 of 9 |
| Piotroski Strength | Weak |
Income Statement
Revenue of $121.83M over the last 12 months is down 14.26% from the 12 months before.
| Revenue | $121.83M |
|---|---|
| Revenue Growth (YoY) | -14.26% |
| Gross Profit | $107.09M |
| Operating Income | -$61.45M |
| Pretax Income | -$53.23M |
| Net Income | -$53.36M |
| Reported EPS (TTM) | -$0.90 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 74.88% of the $340.42M in total assets.
| Cash and Equivalents | $66.72M |
|---|---|
| Total Debt | $8.48M |
| Net Cash | $58.24M |
| Net Cash Per Share | $1.40 |
| Working Capital | $239.85M |
| Shareholder Equity | $254.91M |
| Book Value Per Share | $6.11 |
| Total Assets | $340.42M |
| Total Liabilities | $85.51M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $5.03M of capital spending, operating cash flow left $18.64M of free cash flow.
| Operating Cash Flow | $23.67M |
|---|---|
| Capital Expenditures | $5.03M |
| Free Cash Flow | $18.64M |
| FCF Per Share | $0.45 |
| Depreciation and Amortization | $10.75M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -50.44%, against a 5-year average of -96.25%.
| Gross Margin | 87.90% |
|---|---|
| Operating Margin | -50.44% |
| Pretax Margin | -43.69% |
| Net Margin | -43.80% |
| FCF Margin | 15.30% |
| Gross Margin (5Y Average) | 54.24% |
| Operating Margin (5Y Average) | -96.25% |
| Net Margin (5Y Average) | -90.97% |
Growth
Revenue grew 40.00% a year over 3 years.
| Revenue Growth (3Y CAGR) | +40.00% |
|---|---|
| Revenue Growth (5Y CAGR) | +55.74% |
| Book Value Per Share Growth (2Y CAGR) | +22.53% |
| Tangible Book Per Share Growth (2Y CAGR) | +22.53% |
Dividends and Yields
RXST does not pay a dividend. Its free cash flow yield is 9.26%.
| FCF Yield | 9.26% |
|---|---|
| Buyback Yield | -1.04% |
| Shareholder Yield | -1.04% |
Peer Position
Against 12 similar companies, RXST has the 9th highest P/S.
P/S RatioPeer median 2.9x
ROICPeer median -22.83%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +5.60%
| P/S Ratio | 1.7x vs 2.9x median |
|---|---|
| ROIC | -23.33% vs -22.83% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | -14.26% vs +5.60% median |
Analyst Forecast
Consensus estimates put revenue growth at -7.24% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | -7.24% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About RXST
What is RXST's market cap?
Rxsight has a market cap of $223.06M. Its enterprise value, which adds debt and subtracts cash, is $164.82M.
How many shares of RXST are outstanding?
Rxsight has 41.71M shares outstanding. The count is up 1.81% from a year earlier.
Does RXST pay a dividend?
No. Rxsight does not pay a dividend.
How much debt does RXST have?
Rxsight has $8.48M of total debt and $66.72M of cash and equivalents, a net cash position of $58.24M.
RXST pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors